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yearS of folloW-uP
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Objectives: Determine the persistence, clinic and economic impact of Etanercept 
(ETN) y Adalimumab (ADA) reduced dose in Rheumatoid Arthritis (RA), Psoriatic 
Arthropathy (PA) and Ankylosing Spondylitis (AS) Patients with at least 1 year in 
Clinical Remission MethOds: Observational, retrospective cohort of patients in off-
label program receiving ETN or ADA at reduced dose for at least 6 months (Jan2010 
to Dec2014). Inclusion Criteria: patients treated with ETN or ADA at standard dose 
that achieve and maintain clinical remission (DAS28< 2.6 or BASDAI< 2) during at 
least 1 year were selected to reduce their standard dose.We collected age, sex, indi-
cation, persistence of ETN or ADA at reduced dose during the study period. In these 
patients, we simulated the cost of treatment with ETN or ADA as if they had received 
ETN or ADA at standard dose during their ETN or ADA at reduced dose respec-
tive periods. Economic impact was assessed using Enbrel® and Humira® Spanish 
official prices. Results: From Jan2010 to Dec2014, 144 patients (51% women; age 
51±9 years; 75 RA, 37 PA, 32 AS) received ETN or ADA at reduced dose for at least 0.5 
years. 80 (56%) patients received ETN reduced dose and 64 (44%) patients received 
ADA reduced dose. Patients with ETN reduced dose presented a persistence of 
2,71±1,37years (AR 2,64±1,54, AP 2,56±0,80 y EA 3,04±1,31) and with ADA reduced 
dose presented a persistence of 2,07±0,96years (AR 2,37±0,92, AP 1,86±0,73y EA 
1,74±0,81). Total cost of this low dose strategy throughout the observation period 
were 1.485.510€ . If these patients had been treated with ETN or ADA standard dose, 
the total cost of therapy would have been 2.971.020€ . The implementation of the 
optimized therapy of ETN or ADA saved 1.485.510€ . cOnclusiOns: Reducing the 
dosage of ETN and ADA in selected patients could make treatment more cost-effec-
tive and allow physicians to treat more patients with a fixed budget.
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Objectives: The aim of this study was to explore the treatment protocol of Systemic 
Juvenile Idiopathic Arthritis (SJIA) in Turkey and to assess the impact of pricing and 
reimbursement policies on the treatment budget of SJIA. MethOds: Delphi panel 
method was used in the study. First, a group of rheumatologists answered the Delphi 
panel questionnaire, designed to explore the type and frequency of resources used 
in treatment of SJIA. This was followed by a consensus-building meeting. Budget 
impact was determined by using the Social Security Institution’s related guide-
lines Results: Treatment of SJIA starts with NSAIDs, followed by glucocorticoids 
and DMARDS. Then approximately 40% of the patients, who has not answered the 
agents stated above, continue treatment with biologic agents including anti-TNF 
agents (etanercept, infliksimab, adalimumab), IL-1 (canakinumab) or IL-6 inhibitors 
(tocilizumab). cOnclusiOns: Biologic agents had the largest share in total treatment 
costs mainly because of their relatively higher prices. Some biologics are imported 
from abroad through Turkish Pharma Association as they are not included in posi-
tive list by the Social Security Institution (SSI) yet, adding to the high cost dilemma.
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Objectives: To analyze the changes in pharmacotherapy and their impact on 
costs for 2 years period for patients with rheumatoid arthritis (RA). MethOds: 
The study is retrospective regarding to the cost for the last 1 year (May 2013 - May 
2014) and prospective regarding to the costs for the current therapy (May 2014-May 
2015). It is conducted in all clinical centers that periodically examine chronic RA 
patients. Bottom-up approach was applied using data from the patients’ records 
during their last visit to specialists in the clinical centers. Results: A total 11.83% 
men and 88.17% women with RA were observed. In the age group 51-60 years are 
32.26% of all patients and in the age group over 60 years are 24.73%. 31 patients 
were transferred to biological therapy during their last examination. The average 
RA pharmacotherapy monthly costs for biological drugs, NSAIDs, disease-modifying 
drugs, p.o. corticosteroids and parenteral corticosteroids for 1 year and from now 
on are: 763.60 (SD 296.90) vs. 890.62 (SD 134.58), 5.10 (SD 4.74) vs. 3.54 (SD 3.43), 5.37 
(SD 5.53) vs. 3.40 (SD 4.01), 3.30 (SD 1.40) vs. 2.59 (SD 1.15), 0.37 (SD 0.70) vs. 1.21 
(SD 2.27), respectively. The costs increased significantly (p> 0.05) when biological 
medicines and parenteral corticosteroids started to be prescribed, and decreased for 
the other therapeutic groups mostly due to price revision or new generics entrance. 
Combination of disease-modifying rheumatoid agents (DMRA) and biological treat-
ment is prescribed to 35.5% of the 31 patients on biological therapy. cOnclusiOns: 
The variations in the pharmacotherapy costs are due to wide differences in therapy 
regimes and significantly high costs for biological therapy. Biological treatment 
consumes a significant financial resources but it is an inevitable option especially 
for patients with no effect from disease-modifying drugs.
Objectives: The aim of this study was to assess the disease activity as well as 
indirect costs associated to absenteeism and presenteeism generated by patients 
with ankylosing spondylitis (AS) in a Polish population. MethOds: On-line ques-
tionnaire survey was performed to obtain data on disease activity and the quality 
of life. We used Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with 
additional questions about days missed from work (absenteeism) and decrease of 
on-the-job productivity (presenteeism). BASDAI score was obtained using on-line 
calculator. Total indirect costs were estimated with the Human Capital Approach 
using gross domestic product (GDP) per capita equaled € 10,774 and gross value 
added (GVA) per worker equaled € 25,838. Costs were expressed in 2014 euro. The 
Spearman’s correlation was used to present the association between the disease 
activity and the indirect costs. Results: Total 66 questionnaires were obtained. 
Patients reported mostly the problems with general discomfort and morning stiff-
ness represented by 8 points on BASDAI scale, followed by tiredness and neck pain 
represented by 7 points and other pain represented by 5 points. Almost 30% of 
patients reported that morning stiffness lasts longer than two hours. The mean 
BASDAI score was 5.87 (SD: 1.81). Of all patients 62% were working. Mean number 
of days missed from work was 41 a year (SD: 94) generating indirect cost of € 1,197 
(SD: € 2,776) calculated using GDP per capita and € 2,871 (SD: € 6,657) calculated 
using GVA per worker. Mean decrease of on-the-job productivity was 49% (SD: 24%) 
which was responsible for € 5,287 (SD: € 2,552) and € 12,678 (SD: € 6,120) of indirect 
costs, calculated using GDP per capita and GVA per worker, respectively. Disease 
activity was significantly correlated with indirect costs generated by absenteeism 
(0.271) and presenteeism (0.715). cOnclusiOns: AS is a disease that generates 
huge economic burden. Study revealed that indirect costs are associated with 
the disease activity.
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Objectives: To provide an estimation of expected lifetime numbers, risks, and bur-
den of fractures for 50-year old Chinese women. MethOds: A discrete event simu-
lation model was developed to simulate the lifetime fractures of 50-year old Chinese 
women at the average risk of osteoporotic fractures. Main events in the model 
included hip fracture, vertebral fracture, wrist fracture, humerus fracture, and other 
fracture. Input fracture risks were calculated with the FRAX® tool and the declin-
ing exponential approximation of life expectancy (DEALE) approach. Simulations 
of 50-year old Chinese women without fracture risks were also carried out to 
determine the burden of fractures. Results: For a 50-year old Chinese woman 
at the average risk of fractures, there are 0.135 (95% CI: 0.134-0.137) hip fractures, 
0.120 (95% CI: 0.119-0.122) vertebral fractures, 0.095 (95% CI: 0.094-0.096) wrist frac-
tures, 0.079 (95% CI: 0.078-0.080) humerus fractures, and 0.407 (95% CI: 0.404-0.410) 
other fractures expected for the rest of her life. The residual lifetime risks of any 
fracture, hip fracture, vertebral fracture, wrist fracture, humerus fracture, and other 
fracture for a 50-year old Chinese woman are 37.36%, 11.77%, 10.47%, 8.61%, 7.30%, 
and 27.80%, respectively. The fracture-attributable excess quality-adjusted life year 
(QALY) loss and lifetime costs are estimated at 0.11 QALYs (95% CI: 0.00-0.22 QALYs) 
and US$714.61 (95% CI: US$709.20-720.02), totaling to a net monetary benefit loss 
of US$1,104.43 (95% CI: US$904.09-1,304.78). cOnclusiOns: Chinese women at 
the age of 50 years old are at a high risk of any osteoporotic fracture. The expected 
economic and quality of life burden attributable to fractures among Chinese women 
is substantial.
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Objectives: No adequate data are available about the epidemiology of spinal 
fusion surgery and its economic impact. The objective of this analysis was to 
assess the epidemiologic and economic burden of arthrodesis from a large popula-
tion based-study. MethOds: Lombardy Region includes around 9.9 million indi-
viduals. The study population was identified through a data warehouse (DENALI), 
which matches with a probabilistic linkage demographic, clinical and economic 
data of different Healthcare Administrative databases. The study population was 
made by all subjects who, during the period January 2001–December 2010, under-
went a spinal fusion surgery identified by one of the following codes ICD9-CM: 
81.04 81.05, 81.06, 81.07 and 81.08. The first procedure was used as index event. We 
estimated the incidence of first spinal fusion surgery, the population and surgery 
characteristics and the healthcare costs from the National Health Service’s per-
spective. Results: During the study period, 17,772 (53.2% female) spinal fusion 
surgeries were detected. The results showed an increasing patients’ average age 
during the time period considered. The incidence rate of interventions increased 
from 12.6 to 19.1 per 100,000 person-year in the observational period between 
2001 and 2006. During the last 4 years of observation, the incidence was above 
20.0 per 100,000 person-year. The average hospital length of stay reported for the 
index event was 17.1 days in the 2001 and decreased until 11.0 days in the 2004. 
The average cost of the spinal fusion surgery increased during the observational 
period, from € 4.381 up to € 9,388. cOnclusiOns: The study showed an increas-
ing incidence of spinal fusion surgery and costs from 2001 to 2010 in the Italian 
Lombardy Region. These results can be used to better understand the epidemio-
logical and economic burden of these types of interventions, and help to optimize 
the resources available considering the different surgical procedures available 
today.
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events were considered, reflecting the year 2015. All outcomes were discounted 
at 3.5% annually. Results: Regarding the AS subpopulation, the total treatment 
cost for IFX, ADA, CZP, ETA, GOL and CC was: € 67,736, € 38,914, € 38,721, € 38,290, 
€ 35,338 and € 4,110; and the quality-adjusted life years (QALYs) were: 10.031, 9.882, 
9.949, 9.933, 9.903 and 9.360, respectively. CZP dominated ADA and it was cost-
effective compared to ETA generating an incremental cost-effectiveness ratio 
(ICER) of € 26,848/QALY gained (willingness-to-pay threshold: € 34,000). CZP was 
less effective (-0.082 QALYs) but less costly (-€ 29,015) than IFX, whereas it was 
more effective (+0.046 QALYs) and more costly (+€ 3,383) than GOL. CZP and GOL 
provided the lowest ICERs versus CC amongst comparators. Regarding nr-axSpA, 
the total treatment cost with CC, ADA and CZP was: € 4,754, € 33,748 and € 34,625; 
and QALYs were: 10.412, 10.681 and 10.948. The ICER of CZP versus CC and ADA 
was € 55,726 and € 3,289, respectively; CZP dominated ADA. cOnclusiOns: CZP 
may be considered a cost-effective option with respect to the alternative axSpA 
therapies in Greece.
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Objectives: The aim of this study is to analyze healthcare costs of osteoporosis 
and to build a economic model cost-effectiveness of pharmacological intervents 
based on real world data MethOds: The cost analysis was conducted taking each 
healthcare service into account during the study period (2005-2008). A hypotheti-
cal scenario based on the real-life available evidence was constructed. The mean 
level of adherence to populate the hypothetical scenario of full adherence was set 
at MPR > 80%. The model was built by adding a step value to the real-world adher-
ence of each subject so that the subject shifted to the hypotetical scenario of full 
adherence. Cost-effectiveness of full adherence compared to real-world adherence 
was expressed in terms of ICER and the number of fractures avoided was set as an 
effectiveness unit of measure. Results: The mean annual healthcare cost was 
€ 247.44 per not fractured patient and € 1,044.85 per fractured patient. The eco-
nomic model showed that the average cost of medical treatments in case of optimal 
adherence per patient/year would increase from € 88.73 in real-world adherence 
to € 125.52 in full adherence. The rising costs are compensated by a reduction in 
number of fractures, decreasing by 65%. In this scenario, also the total yearly costs 
related hospitalizations would decrease from € 319,379 in real-word adherence to 
€ 110,917 in full adherence. The ICER, expressed in terms of cost/fracture avoided 
equals € 821 (cost that the NHS should invest to avoide a fracture) cOnclusiOns: 
This study demonstrated the potential of the use of existing data sources to evalu-
ate appropriateness of drug use. Drugs cost money to buy, but if we use them in 
an appropriate way we can also save costs in other areas. In particular enhancing 
adherence to medication may lead to reductions in the number of patients requir-
ing hospitalization.
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Objectives: We assessed the cost-effectiveness of placing apremilast, a new oral 
treatment, before anti-TNFα in the treatment pathway in psoriatic arthritis (PsA) 
patients who had failed ≥ 2 conventional DMARDs, from a Scottish payer perspec-
tive. MethOds: A lifetime Markov cohort model was developed comparing 2 treat-
ment sequences: apremilast followed by adalimumab followed by etanercept vs. 
adalimumab followed by etanercept. Non-responders moved to the next line of 
therapy, or best supportive care (BSC) as last treatment line. Response was assessed 
using the Psoriatic Arthritis Response Criteria (PsARC) at the end of trial periods, 
ranging from 12-16 weeks. A 16.5% annual dropout rate was assumed for each 
drug. Efficacy inputs were obtained from a network meta-analysis and trial results. 
Utilities were estimated from the Health Assessment Questionnaire (HAQ) and 
Psoriasis Area and Severity Index response using a published regression equation. 
The HAQ score was assumed to progress in BSC. Unit costs were sourced from the 
British National Formulary, NHS reference costs, and other published sources, with 
apremilast priced at £550/4-week cycle. A 3.5% annual discount rate was applied to 
costs and quality-adjusted life-years (QALYs). Results: The apremilast arm pro-
vided an additional 2.49 years with a PsARC response and an additional 0.78 QALYs. 
Total time spent on anti-TNFα agents was reduced by 0.33 years, and time spent 
in BSC was reduced by 2.79 years. Under base-case assumptions, placing apremi-
last before anti-TNFα was more effective and less costly (incremental QALYs: 0.71; 
cost: £11,695), resulting in a cost of £16,507/QALY gained. Structural and param-
eter assumptions were tested in sensitivity analyses, which indicated results were 
sensitive to several parameters (e.g., HAQ increase on BSC, discount rates, cost of 
BSC). cOnclusiOns: Placing apremilast before anti-TNFα agents is cost-effective 
in PsA treatment. Apremilast has been recommended for use in Scotland for the 
management of PsA patients.
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Objectives: Assess the model structure, treatment sequence and outcome in con-
temporary cost effectiveness analysis (CEA) studies in the US and UK. MethOds: 
Studies on conventional and biologic Disease-modifying anti-rheumatic drugs 
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Objectives: Rheumatoid arthritis (RA) is a chronic, inflammatory disorder lead-
ing to disability and reduced quality of life. Effective treatment with biologic 
disease-modifying antirheumatic drugs (bDMARDs) is a significant economic 
burden on the Italian healthcare system. Economic models comparing bDMARDs 
are commonly based on indirect treatment comparisons. The Abatacept ver-
sus Adalimumab Comparison in Biologic-Naive RA Subjects with Background 
Methotrexate (AMPLE) trial was a head-to-head randomized study comparing 
subcutaneous abatacept to adalimumab, both combined with methotrexate, in 
RA patients. This study evaluated the cost-effectiveness of abatacept relative to 
adalimumab for RA patients based on AMPLE from the Italian National Health 
Service (NHS) perspective. MethOds: A decision tree was designed to compare 
the costs and health benefits of abatacept and adalimumab in a cohort of 1,000 
patients over a 2-year time horizon. Efficacy, safety and concomitant drug use 
was based on AMPLE. Health benefits were based on stringent efficacy criteria: 
American College of Rheumatology (ACR)70/90 response and the health assess-
ment questionnaire disability index (HAQ-DI). Unit costs were estimated from pub-
lished public prices for 2014. Univariate sensitivity analyses assessed uncertainty 
of model inputs. Results: Abatacept dominated adalimumab in the treatment of 
RA patients with its higher effectiveness and lower costs over 2 years. Total health 
benefits were higher for abatacept compared to adalimumab, with 18, 63 and 
53 additional patients achieving ACR70, ACR90 and HAQ-DI response. Total costs 
favoured abatacept over adalimumab, with cost-savings of € 237,246. Cost-savings 
were due to lower costs for bDMARDs (-€ 262,527), treatment-related serious AEs 
(-€ 121,764), and local injection site reactions (-€ 14,047). Sensitivity analyses show 
that the cost-savings are robust while the difference in health benefits is sensi-
tive to parameter variation. cOnclusiOns: For the Italian NHS, abatacept is less 
costly and more effective than adalimumab for RA patients according to ACR70, 
ACR 90, and HAQ-DI outcomes based on the AMPLE trial.
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Objectives: Psoriatic arthritis (PsA) treatment may involve use of biologic injec-
tions/infusions. Apremilast was recently approved for treatment of adults with 
active PsA. Oral apremilast is priced significantly lower than biologics. Published 
comparative healthcare cost data are lacking for PsA patients receiving apremilast 
vs. biologics in a real-world care setting. We compared healthcare costs among 
PsA patients initiating apremilast or a biologic from the US managed care perspec-
tive. MethOds: Adults with ≥ 2 diagnosis codes for PsA (ICD-9:696.0) were selected 
from the 2014-2105 MarketScan Commercial and Medicare Supplemental database. 
The first prescription date was defined as the index date; patients had to be continu-
ously enrolled for ≥ 6 months pre-index and ≥ 3 months post-index. To ensure new 
patient starts, biologic users had to be treatment-naïve to index medication in the 
pre-index period, although prior use of another biologic was not reason for exclu-
sion. Healthcare costs (2014 US$) were defined as the sum of pharmacy+medical 
service costs (e.g., inpatient, outpatient [including intravenous infusions], emer-
gency, and all other services [laboratory, radiology, other ancillary services]). Results, 
expressed as cost/patient/month, were reported separately for disease-specific PsA 
costs. Results: 469 (apremilast) and 1,120 (biologics) patients met inclusion cri-
teria; mean enrollment post-index was 5.6 and 6.5 months, respectively. Baseline 
demographics were balanced between cohorts, except mean age (apremilast: 52.9y; 
biologics: 49.8y; P< 0.001) and mean Charlson Comorbidity Index score (apremilast: 
0.8; biologics: 0.7; P= 0.016). Mean monthly costs for initiating apremilast vs. biologics 
were: all healthcare, $3,198 vs. $4,247 (P< 0.001); all PsA-related healthcare, $2,301 vs. 
$3,447 (P< 0.001), including PsA-related pharmacy, $2,095 vs. $2,617 (P< 0.001); PsA-
related inpatient, $43 vs. $48 (P= 0.776); PsA-related emergency, $4 vs. $10 (P= 0.456); 
PsA-related outpatient, $155 vs. $767 (P< 0.001); and all other PsA-related services, 
$4 vs. $5 (P= 0.748). cOnclusiOns: Apremilast cost less than biologics, with aver-
age savings of ≈$1,000/patient/month based on lower PsA-related pharmacy and 
PsA-related outpatient costs.
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Objectives: To evaluate the cost-effectiveness of certolizumab pegol (CZP) in 
the treatment of axial spondyloarthritis (axSpA), including ankylosing spondy-
litis (AS) and non-radiographic axSpA (nr-axSpA), from a Greek payer perspec-
tive. MethOds: A Markov model was locally adapted to evaluate the health effects 
and associated costs of CZP, adalimumab (ADA), infliximab (IFX), etanercept (ETA), 
golimumab (GOL) and conventional care (CC) in AS; and CZP, ADA and CC in nr-
axSpA. The model incorporated clinical practice patterns and the natural history 
of axSpA, following patients from treatment initiation to death. Efficacy data from 
randomized trials of comparators were included in a meta-analysis of a mixed 
treatment comparison analysis. The assessment period for AS and nr-axSpA was 
24 and 12 weeks, respectively. Direct costs for treating axSpA (medication acqui-
sition, administration, monitoring, and healthcare visits) and managing adverse 
